Accelerated FDA approval of Kyprolis™ (carfilzomib) for Injection
Congratulations to Onyx Pharmaceuticals on the accelerated FDA approval of Kyprolis™ (carfilzomib) for Injection, a proteasome inhibitor for the treatment of patients with multiple myeloma. Read the official press release.
For some analysts take on business ramifications, see:
http://www.onclive.com/web-exclusives/FDA-Approves-Carfilzomib-for-Relapsed-Multiple-Myeloma,
http://www.fiercepharma.com/
Disclaimer: CDD’s Barry Bunin was on one of the early patents for carfilzomib: Smyth, M. S.; Laidig, G. J; Borchardt, R. T.; Bunin, B. A.; Crews, C. M.; Musser, J. H.; Schneekloth, J. S.; Chabala, J. C. Compounds for Enzyme Inhibition. Patent No. US 2005/0245434 A1; issued 3 Nov 2005 (Proteolix, Inc). Proteolix was acquired by Onyx Pharmaceuticals:
This blog is authored by members of the CDD Vault community. CDD Vault is a hosted drug discovery informatics platform that securely manages both private and external biological and chemical data. It provides core functionality including chemical registration, structure activity relationship, chemical inventory, and electronic lab notebook capabilities!
CDD Vault: Drug Discovery Informatics your whole project team will embrace!
Other posts you might be interested in
View All Posts
CDD Vault Updates
5 min
January 29, 2025
CDD Vault Update (January 2025): New Curve Fits, Exponential Decay and Scatter Plot, Hide Outliers in Plot Export, Register an AI Generated Molecule, Create Custom Molecule Optimization Scores
Read More
CDD Blog
8 min
January 9, 2025
Drug Discovery Industry Roundup with Barry Bunin — January 9th, 2025
Read More
CDD Vault Updates
3 min
January 6, 2025
CDD Vault Update (December #2): Create a Sample from a Debit, Suggest Bioisosteres for Unregistered Structures, Copy Protocols Across Vaults
Read More